UCB, Inc. - Recruiting 20 years or older. - Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine in Depressive Symptoms in Idiopathic Parkinson's Disease Patients.
UCB, Inc. - Recruiting 30 years or older. - A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On Levodopa.
Teva Pharmaceutical Industries - Recruiting 45 years to 80 years. - A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older. - A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease.
University of Massachusetts, Worcester - Recruiting 18 years or older. - A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy.
InSightec - Recruiting 30 years or older. - A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease..
KineMed - Recruiting 18 years or older. - Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases.
Luye Pharma Group Ltd. - Recruiting 18 years or older. - A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections.
Hospices Civils de Lyon - Recruiting 40 years to 70 years. - Pathophysiology of Non Motor Signs and Compensatory Mechanisms in Parkinson's Disease: Role of the Serotoninergic and Dopaminergic Lesions Studied by PET.
GlaxoSmithKline - Recruiting 40 years to 80 years. - A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying.
Kyowa Hakko Kirin Pharma, Inc. - Recruiting 30 years or older. - A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease.
Department of Veterans Affairs - Recruiting 21 years to 95 years. - CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort.
Pharma Two B Ltd. - Recruiting 35 years to 75 years. - A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease.
Pramipexole / Rasagiline Mesylate once daily; Placebo
University of Texas Southwestern Medical Center - Recruiting 30 years or older. - Longitudinal, Single-center Prospective Study to Assess Progression of Clinical Features and Biologic Markers of Parkinson's Disease Subjects of Varying Levels of Disease Severity.
Rhythm Pharmaceuticals, Inc. - Recruiting 18 years to 80 years. - A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients With Parkinson's Disease and Chronic Constipation Dissatisfied With Current Therapy.
AbbVie - Recruiting 30 years or older. - An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications.
AbbVie - Recruiting 18 years or older. - Analysis of MOtor and NOn Motor Symptoms, Quality of Life and Occurence of Dyskinesias in Advanced Parkinson's Disease Patients With 2 to 4 Hours 'Off-time' and Without Troublesome Dyskinesias Under Duodopa TREATment - a Multi-country Post-marketing Observational Study -MONOTREAT.
AbbVie - Recruiting 30 years or older. - An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease.
Rennes University Hospital - Recruiting 18 years or older. - Prospective, Randomised, Comparative Study Comparing Efficacy of Continuous Apomorphine Infusion Versus Usual Dopaminergic Per os Treatment on Cognitive and Neuropsychological Functions in Parkinson's Disease: a Clinical and PET-scan Study.
Continuous Apomorphine infusion; Usual dopaminergic per os treatment
Oslo University Hospital - Recruiting 18 years to 75 years. - Prognostic Factors in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) - a Prospective Randomized Double-blind Study (The NORSTIM Study).
Washington University School of Medicine - Recruiting 40 years to 70 years. - Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in PD Without Dementia.
Istanbul University - Recruiting N/A or older. - The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 Months.